[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627353":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":36,"centralContacts":40,"locations":46,"responsibleParty":65,"collaborators":44,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":44,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":44,"enrollmentInfo":78,"targetDuration":44,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":44,"overallStatus":49,"whyStopped":44,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University of Iowa","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Diagnostic (T2* MRI, blood sample collection)","EXPERIMENTAL","Patients undergo T2\\* MRI over 10 minutes and blood sample collection during radiation therapy simulation, weekly during radiation therapy, and at 1- and 3- months post-radiation therapy in the absence of unacceptable toxicity. Patients also undergo standard MRI throughout the study.",[13,14,15],"Procedure: T2 (Observed)-Weighted Imaging","Procedure: Biospecimen Collection","Procedure: Magnetic Resonance Imaging",[17,24,30],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"PROCEDURE","T2 (Observed)-Weighted Imaging","Undergo T2\\* MRI",[9],[23],"T2*-Weighted Imaging, T2*MRI, T2*WI",{"type":18,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"Biospecimen Collection","Undergo blood sample collection",[9],[29],"Biological Sample Collection, Biological Sample Collection, Biospecimen Collected, Biospecimen Collection, Specimen Collection",{"type":18,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"Magnetic Resonance Imaging","Undergo standard MRI",[9],[35],"Magnetic Resonance, Magnetic Resonance Imaging, Magnetic Resonance Imaging, Magnetic Resonance Imaging, magnetic resonance imaging, Magnetic Resonance Imaging, Magnetic Resonance Imaging",[37],{"name":38,"affiliation":5,"role":39},"John Buatti, MD","PRINCIPAL_INVESTIGATOR",[41],{"name":38,"role":42,"phone":43,"phoneExt":44,"email":45},"CONTACT","(319) 356-7590",null,"john-buatti@uiowa.edu",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"University of Iowa Health Care","RECRUITING","Iowa City","Iowa","52245","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-91.53017,41.66113,{"lat":59,"lon":58},[62,64],{"name":38,"role":42,"phone":63,"phoneExt":44,"email":45},"319-356-7590",{"name":38,"role":42,"phone":43,"phoneExt":44,"email":45},{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"SPONSOR_INVESTIGATOR","John M. Buatti","Professor","100627353","t2-star-magnetic-resonance-imaging-and-biomarker-blood-testing-to-predict-the-change-and-progress-of-malignant-gliomas-100627353",false,"NCT07447531","T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas","Evaluating Iron-Dependent Biomarkers of Malignant Glioma (WHO Grade IV) Progression","Inclusion Criteria:\n\n* Age \\> 21 years\n* New pathologically confirmed diagnosis of WHO grade IV malignant glioma\n* KPS \\> 60\n* Ability to give informed consent for standard of care chemotherapy and radiation therapy on the MR Linac and to study procedures for the protocol\n\nExclusion Criteria:\n\n* History of previous malignancy other than non-melanoma skin cancer in the previous 5 years\n* History of iron metabolic disorder such as hemochromatosis\n* Inability to undergo MR studies due to size, claustrophobia, or metal implants or devices","ALL","21 Years",{"count":79,"type":80},15,"ESTIMATED","INTERVENTIONAL",[83],"NA","This clinical trial studies whether T2 star (T2\\*) magnetic resonance imaging (MRI) and biomarker blood testing can help predict how World Health Organization (WHO) grade IV gliomas (malignant gliomas) might change or progress over time.",[86],"Malignant Glioma","2026-02-25",{"date":89,"type":90},"2026-03-03","ACTUAL",{"date":92,"type":90},"2025-10-03",{"date":94,"type":80},"2028-10-06",{"name":67,"class":6},1]